
Celltrion Launches Autoimmune Disease Treatment 'Steqeyma' in the U.S.
Celltrion has officially launched its autoimmune disease treatment, 'Steqeyma®' (active ingredient: ustekinumab), in the United States, the world's largest pharmaceutical market, on March 12th (local time). Steqeyma is a biosimilar developed by …